UNIFARM SA, Romania’s state-owned pharmaceutical company operating under the Ministry of Health, has completed the 2022–2026 period with a full financial recovery. The figures were presented by Health Minister Alexandru Rogobete and reported by Forbes.
According to the published data, UNIFARM has reached a turnover of more than RON 274 million and no longer carries historical debt. In 2022, the company’s total liabilities exceeded RON 1.26 billion, including over RON 1 billion owed to the state budget.
Balance sheet recovery and business growth
Read also: Eli Lilly becomes the first drugmaker in the world to reach a $1 trillion market valuation
The full repayment of outstanding obligations was accompanied by a major correction of the company’s balance sheet. Equity moved from a negative level of around RON –708 million in 2022 to a positive figure exceeding RON 68 million at present, reflecting financial rebalancing after several years of losses and structural imbalances.
The activity report for 2022–2026 shows a sharp expansion of operations. Turnover increased from approximately RON 79 million in 2022 to more than RON 274 million today. At the same time, UNIFARM significantly broadened its portfolio, from just three active molecules to over 1,300 products, currently supplying hundreds of hospitals and thousands of pharmacies.
Between 2023 and 2025, UNIFARM delivered plasma-derived products, noradrenaline to nearly 300 healthcare units, as well as antivirals for hospitals and pharmacies. The Ministry of Health notes that the financial recovery coincided with expanded operational capacity, supported by GDP and ISO certifications and marketing authorizations for a wide range of pharmaceutical products.
Photo: MedikaTV
UK
IT
ES
DE
FR
RO
PT
HU
